Mabtech and Sai Life Sciences Announce Strategic Collaboration for Immunology Research

The partnership establishes Sai's Boston lab as a co-marketed US execution and demonstration hub for Mabtech's EYRA platform.

Jan. 28, 2026 at 4:55am

Got story updates? Submit your updates here. ›

Mabtech, a global life science tools company, and Sai Life Sciences, a leading Contract Research, Development, and Manufacturing Organization (CRDMO), have announced a strategic collaboration that establishes Sai's Boston laboratory as a co-marketed US execution and demonstration hub for Mabtech's EYRA platform. Under this partnership, the companies will jointly deliver advanced immunology assay services, including high-sensitivity multiplex cytokine and phenotyping workflows, powered by the EYRA platform installed at Sai's Boston discovery site.

Why it matters

This collaboration aims to accelerate access to next-generation immune profiling capabilities for biopharma and biotech companies working in areas like immuno-oncology, vaccines, inflammation, and cellular therapy. By integrating Mabtech's assay expertise and Sai's discovery and translational capabilities, the partnership creates a new service offering to support complex programs in immunology and immuno-oncology.

The details

The EYRA platform incorporates intuitive software, automation readiness, and simultaneous detection of dozens of analytes in a single run with minimal hands-on time. This collaboration allows Sai to offer EYRA's powerful, no-flow multiplex immunology readouts to their broad customer base, expanding access to high-quality, reproducible immune profiling. The partnership also includes joint service delivery of EYRA-based immunology panels and custom assays, co-branded demonstrations and pilot programs at Sai Boston, shared thought leadership and case study development, and integrated business development engagement supporting discovery through translational research.

  • The strategic collaboration was announced on January 28, 2026.

The players

Mabtech

A Swedish life science tools company delivering high-quality immunoassays, reagents, and instrumentation to support advanced immunology research worldwide.

Sai Life Sciences

A full-service Contract Research, Development, and Manufacturing Organization (CRDMO) working with innovator pharma and biotech companies globally to accelerate the discovery, development, and commercialization of small molecules and emerging modalities.

Kimberlee Parent

Head of US Operations at Mabtech.

Maneesh Pingle

Head of Discovery Services at Sai Life Sciences.

Got photos? Submit your photos here. ›

What they’re saying

“We're excited to see EYRA placed at Sai Life Sciences and integrated into their US discovery operations. This installation enables Sai to offer EYRA's powerful, no-flow multiplex immunology readouts to their broad customer base, expanding access to high-quality, reproducible immune profiling. Together, Mabtech's assay expertise and Sai's strong discovery and translational capabilities create a compelling new service offering for researchers.”

— Kimberlee Parent, Head of US Operations at Mabtech (Globe Newswire)

“For our discovery clients, the ability to generate reliable, decision-enabling data early is critical. By establishing our Boston site as a US execution hub for EYRA-enabled immunology workflows, we are strengthening Sai's capability to support complex programs in immunology and immuno-oncology. This collaboration with Mabtech allows us to integrate advanced immune profiling seamlessly into broader discovery and translational strategies—helping teams move from biological hypothesis to confident development decisions faster.”

— Maneesh Pingle, Head of Discovery Services at Sai Life Sciences (Globe Newswire)

The takeaway

This strategic collaboration between Mabtech and Sai Life Sciences aims to accelerate access to next-generation immune profiling capabilities for biopharma and biotech companies, particularly in the areas of immuno-oncology, vaccines, inflammation, and cellular therapy. By integrating Mabtech's assay expertise and Sai's discovery and translational capabilities, the partnership creates a compelling new service offering to support complex programs in immunology and immuno-oncology research.